Drug manufacturer Unichem said a HRSA 340B compliance audit found that it overcharged just two facilities and must repay them just $110.20.
Generic drug manufacturer Unichem says a 340B compliance audit found it overcharged just two entities and the repayment to both totals just $110.20.

Unichem Says 340B Audit Found it Overcharged Just Two Entities and Must Repay Them Just $110.20

Late last month, the U.S. Health Resources and Services Administration (HRSA) said on its website that generic drug manufacturer Unichem Pharmaceuticals USA had to repay 340B covered entities for overcharges found during a 340B program compliance audit.

According to Unichem, the audit found it overcharged only two entities and the repayment to both totals just $110.20. “Unichem cooperated fully with the audit process and is refunding those two facilities,” the company said. It said its audit covered six months of 340B ceiling price calculations and 340B pricing offered to over 11,100 eligible facilities.

Generic drug manufacturer Unichem says a 340B compliance audit found it overcharged only two entities and the repayment to both totals just $110.20.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report